This site is intended for health professionals only

ERS: Moxifloxacin ‘demostrates non-inferiority for COPD’


Bayer HealthCare announced positive results from the MAESTRAL (moxifloxacin in acute exacerbations trial) study at the European Respiratory Society (ERS) Congress in Amsterdam this weekend.

MAESTRAL compared the efficacy of Avelox┬« (moxifloxacin HCI) to that of the gold-standard beta-lactam comparator – amoxicillin/clavulanic acid – in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

The primary endpoint of the study was clinical failure within eight weeks post-therapy. The study demonstrated non-inferiority between five days of moxifloxacin once daily and seven days of amoxicillin/clavulanic acid twice daily.

Moreover, in a pre-planned analysis moxifloxacin demonstrated significantly lower clinical failure rates compared with amoxicillin/clavulanic acid at eight weeks post-therapy in patients with bacteriologically confirmed exacerbations.

“MAESTRAL has given us some very exciting data showing that bacterial eradication leads to better clinical outcomes,” said principal investigator Dr Robert Wilson from the Royal Brompton Hospital in London, UK.
“Moxifloxacin provides a real benefit in patients with bacterial AECOPD.”

Bayer Healthcare

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine